BMS-986482

Table of contents

• What is BMS-986482?
• How does BMS-986482 work?
• Which conditions is BMS-986482 studied for?
• How is BMS-986482 given?
• What do the clinical trials show?
• What side effects are known?

What is BMS-986482?

BMS-986482 is an investigational medicine that is being developed for the treatment of cancer. It is not yet authorised as a medicine and is currently being studied in clinical trials. The substance is given by mouth, which means it is taken orally.^[1]

The full name of the substance is BMS-986482. In the trial record, it is listed as an intervention given by oral use. The trial also includes other cancer medicines: nivolumab given as a subcutaneous injection, a fixed-dose combination of nivolumab and relatlimab given as a subcutaneous injection, and bevacizumab given as a solution for infusion.^[1]

How does BMS-986482 work?

The registry record for this trial does not describe the mechanism of action of BMS-986482. What is known from the trial design is that BMS-986482 is being tested both on its own and together with other cancer medicines that work in different ways. Nivolumab and relatlimab are immune checkpoint inhibitors, and bevacizumab is a medicine that blocks the growth of blood vessels that feed tumors. The study will help show how BMS-986482 behaves when given alone or with these other medicines.^[1]

Which conditions is BMS-986482 studied for?

The trial studies BMS-986482 in one broad group of conditions:

• Advanced solid tumors — cancers that have spread from where they started and cannot be removed by surgery. The trial does not limit participation to one specific cancer type.^[1]

How is BMS-986482 given?

BMS-986482 is given by mouth, which means it is taken orally. In the trial, the other medicines are given in different ways: nivolumab is given as a subcutaneous injection under the skin; the fixed-dose combination of nivolumab and relatlimab is also given as a subcutaneous injection; and bevacizumab is given as a solution for infusion into a vein.^[1]

What do the clinical trials show?

There is one clinical trial of BMS-986482 registered in the data provided. It is a Phase 1/2 study, which means it is an early-stage trial that first tests safety and dosing in a small group of people and then begins to look at how well the medicine works. The trial is currently authorised, which means it has received approval to begin but is not yet recruiting participants.^[1]

The trial plans to enroll 90 participants with advanced solid tumors. Participants will receive BMS-986482 alone or in combination with one of three other treatments: nivolumab subcutaneous, the fixed-dose combination of nivolumab and relatlimab subcutaneous, or bevacizumab.^[1]

The main outcome the trial measures is safety. The researchers will record the number of adverse events, serious adverse events, adverse events that meet the criteria for dose-limiting toxicity, adverse events that lead to stopping treatment, and deaths. A dose-limiting toxicity is a side effect that is severe enough to prevent giving a higher dose of the medicine. The trial also aims to find the recommended Phase 2 dose, which is the dose that will be used in later, larger studies.^[1]

Because the trial is not yet recruiting and no results have been published, there are no findings yet about how well BMS-986482 works against cancer or what side effects it causes in people.

What side effects are known?

The registry record does not list side effects that have already been observed with BMS-986482. The purpose of the ongoing trial is to find out what side effects occur and how often. The trial records adverse events, serious adverse events, dose-limiting toxicities, and adverse events that lead to stopping treatment as its main outcome measures.^[1]